Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been given a consensus recommendation of "Buy" by the eight research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $11.50.
A number of brokerages have weighed in on ACRS. Wedbush boosted their price target on Aclaris Therapeutics from $8.00 to $10.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 29th. Wall Street Zen raised Aclaris Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 16th. UBS Group set a $10.00 price objective on Aclaris Therapeutics in a research note on Thursday, April 16th. Weiss Ratings restated a "sell (d-)" rating on shares of Aclaris Therapeutics in a report on Wednesday, June 24th. Finally, Piper Sandler upped their target price on Aclaris Therapeutics from $7.00 to $11.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 5th.
Read Our Latest Report on ACRS
Institutional Trading of Aclaris Therapeutics
A number of hedge funds have recently bought and sold shares of ACRS. Invesco Ltd. boosted its position in shares of Aclaris Therapeutics by 409.0% during the 1st quarter. Invesco Ltd. now owns 57,079 shares of the biotechnology company's stock valued at $87,000 after acquiring an additional 45,864 shares in the last quarter. Millennium Management LLC raised its position in Aclaris Therapeutics by 111.0% in the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company's stock worth $6,325,000 after purchasing an additional 2,175,101 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Aclaris Therapeutics by 29.7% in the first quarter. Goldman Sachs Group Inc. now owns 555,953 shares of the biotechnology company's stock worth $851,000 after purchasing an additional 127,366 shares in the last quarter. Geode Capital Management LLC lifted its stake in Aclaris Therapeutics by 108.4% during the second quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company's stock worth $3,501,000 after purchasing an additional 1,282,042 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Aclaris Therapeutics by 25.1% during the second quarter. JPMorgan Chase & Co. now owns 623,792 shares of the biotechnology company's stock worth $886,000 after purchasing an additional 125,071 shares during the period. 98.34% of the stock is owned by institutional investors.
Aclaris Therapeutics Trading Down 0.2%
NASDAQ:ACRS opened at $5.90 on Tuesday. The firm has a market capitalization of $824.94 million, a price-to-earnings ratio of -10.17 and a beta of 0.78. Aclaris Therapeutics has a 1-year low of $1.58 and a 1-year high of $6.51. The business's fifty day moving average price is $5.16 and its 200 day moving average price is $4.35.
Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. The firm had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.38 million. Equities analysts forecast that Aclaris Therapeutics will post -0.64 earnings per share for the current year.
Aclaris Therapeutics Company Profile
(
Get Free Report)
Aclaris Therapeutics, Inc NASDAQ: ACRS is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company's pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.
Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Aclaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.
While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
